KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Operating Leases (2019 - 2026)

Bio-Rad Laboratories has reported Operating Leases over the past 8 years, most recently at $138.6 million for Q1 2026.

  • Quarterly Operating Leases fell 17.3% to $138.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $138.6 million through Mar 2026, down 17.3% year-over-year, with the annual reading at $145.7 million for FY2025, 10.88% up from the prior year.
  • Operating Leases was $138.6 million for Q1 2026 at Bio-Rad Laboratories, down from $145.7 million in the prior quarter.
  • Over five years, Operating Leases peaked at $206.3 million in Q3 2023 and troughed at $131.4 million in Q4 2024.
  • The 5-year median for Operating Leases is $183.1 million (2023), against an average of $173.8 million.
  • Year-over-year, Operating Leases surged 40.15% in 2023 and then tumbled 30.24% in 2024.
  • A 5-year view of Operating Leases shows it stood at $189.9 million in 2022, then fell by 12.85% to $165.5 million in 2023, then fell by 20.6% to $131.4 million in 2024, then grew by 10.88% to $145.7 million in 2025, then decreased by 4.87% to $138.6 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's Operating Leases are $138.6 million (Q1 2026), $145.7 million (Q4 2025), and $192.6 million (Q3 2025).